Skinvisible: $120 cash, $9.9M liabilities, Quoin deal offers hope amid collapse risk

Skinvisible, Inc. (OTCBB: SKVI) - Quick read

Key facts & statistics
Cash at June 30, 2025: $120
Revenues: $5,000 (Q2 2025); $10,000 (six months 2025) - flat vs. 2024
Gross profit: $5,000 (Q2); $10,000 (six months)
Net loss: $(274,427) (Q2 2025) vs. $(303,449) (Q2 2024)
Net loss: $(555,432) (six months 2025) vs. $(593,821) (six months 2024)
Basic loss per share: $(0.05) (Q2 2025); $(0.10) (six months 2025)
Shares outstanding (Aug 13, 2025): 5,403,843
Potential additional dilution: 82,346,405 shares issuable (convertible notes, warrants, options)
Total current assets: $33,102; Total assets: $143,375 (June 30, 2025)
Total current liabilities: $4,525,151; Total liabilities: $9,897,554
Accrued interest payable: $3,068,780
Convertible notes payable - related party: $5,372,403
Stockholders' deficit: $(9,754,179)
Working capital deficit: $4,492,049 (June 30, 2025)
Warrants outstanding: 189,000 (WA exercise price $0.57)

What's happening inside
Management has completed R&D on ~40 formulary products and holds patents around its Invisicare polymer delivery platform. The company generates minimal revenue from product sales and licenses today but is focused on monetizing via licensing and partnerships. The largest near-term commercial catalyst is the licensed program with Quoin Pharmaceuticals (QRX003) - Quoin progress includes FDA IND acceptance, clinical expansions, and regulatory designations (EMA orphan designation and FDA Rare Pediatric Disease designation in 2025). Meanwhile, Skinvisible's balance sheet shows urgent liquidity pressure and heavy related‑party convertible debt.

Income statement - Positive aspects
Revenue stability: Q2 and six‑month revenues matched 2024 ($5,000 / $10,000) - at least consistent.
Net loss improved year‑over‑year: Q2 loss narrowed from $(303,449) to $(274,427); six‑month loss improved from $(593,821) to $(555,432).
Interest expense trending down: interest expense six months $283,873 vs. $333,018 in prior year six months (reduces cash burden if trend continues).
Low cost of goods sold: cost of revenues reported as $0, producing small gross profit on tiny sales (high margin in current mix).

Income statement & financial statement - Negative aspects
Revenue negligible: $5,000 in a quarter is immaterial to cover overhead or service liabilities.
Severe liquidity crisis: cash $120 at quarter end; operating cash flow usage and financing needs are acute.
Massive liabilities vs. tiny assets: total liabilities $9.9M vs. assets $143k; stockholders' deficit $(9.75M).
Large related‑party convertible debt: $5,372,403 convertible note balance concentrated with related parties - risk of conversion/dilution and governance concerns.
High accrued interest payable: $3,068,780 - adds near‑term cash strain and increases debt burden.
Material weaknesses: management identified ineffective disclosure controls and internal control deficiencies - remediation contingent on raising capital.
Significant potential dilution: 82.3M additional shares issuable from convertibles/warrants/options - can severely dilute existing holders if converted.
Going concern: management states substantial doubt about ability to continue as a going concern within 12 months.

Risks, catalysts and near‑term priorities
Catalysts: Quoin's clinical progress and regulatory designations for QRX003 - potential milestone receipts, royalties, and a $5M milestone on regulatory approval per license terms (and expanded sublicense revenue prospects).
Risks: immediate need for financing (private equity, debt or licensing receipts). Failure to raise funds could force asset sales, restructuring, or dilution on unfavorable terms.
Governance/controls: identified material weaknesses must be addressed to restore investor confidence and meet SEC/GAAP reporting expectations.
Dilution and related‑party concentration: convertible instruments and related‑party debt represent both a refinancing source and a dilution/governance risk.

Bottom line - Straightforward view
Skinvisible owns a patented delivery platform with real R&D assets and a potentially valuable licensing pipeline (notably the Quoin QRX003 program). However, the company's financials show critical short‑term survival issues: almost no cash, a large working capital deficit, significant related‑party convertible debt, and material weaknesses in controls. Until meaningful licensing payments, successful capital raises, or material revenue growth occur, the investment thesis rests on future catalysts (Quoin milestones/regulatory wins) and management's ability to secure financing without catastrophic dilution.

If you want, I can prepare a one‑page investor snapshot focused on liquidity scenarios, dilution math, and a timeline of Quoin milestones.